<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256800</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-20130020</org_study_id>
    <nct_id>NCT02256800</nct_id>
  </id_info>
  <brief_title>Escalated Dose of Irinotecan in mCRC</brief_title>
  <official_title>Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaw-Yuan Wang, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic diseases were found in 20-25% of patients with initial diagnosis of colorectal&#xD;
      cancer and developed in up to 50% of patients. Owing to limited post-treatment response of&#xD;
      5-fluorouracil (5-FU) combined with leucovorin (LV) obtained in mCRC (metastatic colorectal&#xD;
      cancer) patients, other therapeutic agents with different mechanisms were considered, such as&#xD;
      irinotecan, a potent inhibitor of topoisomerase I, which is involved in the unwinding of DNA&#xD;
      during replication. Bevacizumab is a humanized monoclonal antibody that inhibits tumor&#xD;
      angiogenesis by blocking vascular endothelial growth factor (VEGF) and was the first&#xD;
      antiangiogenic agent approved for the treatment of cancer.&#xD;
&#xD;
      Infusional fluorouracil/leucovorin plus irinotecan-based regimen (FOLFIRI) with bevacizumab&#xD;
      has been widely used as first-line treatment for patients with metastatic colorectal cancer&#xD;
      (mCRC). Recently, the investigators have shown that prospective analysis of uridine&#xD;
      diphosphate glucuronosyl transferase 1A1 (UGT1A1) genotyping for irinotecan dose escalation&#xD;
      (FOLFIRI regimen) with combination of bevacizumab biweekly as the first-line setting in mCRC&#xD;
      patients (ASCO Abstract #491 - 2013 Gastrointestinal Cancers Symposium).&#xD;
&#xD;
      In this study, the investigators will enroll approximately 320 mCRC patients (It was&#xD;
      considered that an increase of response rate of 15% compared to conventional irinotecan dose&#xD;
      of 180 mg/m2, and these were chosen as parameters with which to calculate the study power.&#xD;
      Initial power calculation was suggested that a minimum of 140 patients in each group would be&#xD;
      required to achieve statistical significance with a power of 80% at the 5% significance&#xD;
      level. It is estimated that about 10% of 320 mCRC patients fail to complete the study). For&#xD;
      these enrolled patients, the investigators will randomize and divide these patients into two&#xD;
      groups: control group and study group. Control group includes mCRC patients who will receive&#xD;
      the conventional regimen of FOLFIRI plus bevacizumab. Otherwise, patients in the study group&#xD;
      will have genotyping of UGT1A1 before therapy, and dose escalating of irinotecan will depend&#xD;
      on results of genotyping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control group:&#xD;
&#xD;
      Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1,&#xD;
      follow by irinotecan (180 mg/m2 as a 120-min IV infusion), LV (400 mg/m2 IV infusion over 2&#xD;
      hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
&#xD;
      Study group: FOLFIRI (infusional fluorouracil/leucovorin plus irinotecan) + Bevacizumab. The&#xD;
      dosage of irinotecan is adjusted to the UGT1A1 genotyping&#xD;
&#xD;
      The wild-type (6/6) of UGT1A1:&#xD;
&#xD;
      Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1,&#xD;
      follow by irinotecan (180 mg/m2 as a 120-min IV infusion), LV (400 mg/m2 IV infusion over 2&#xD;
      hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
&#xD;
      After 2 cycles of each different dose of irinotecan, we will observe the adverse effects&#xD;
      (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will&#xD;
      escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260&#xD;
      mg/m2.&#xD;
&#xD;
      The (6,7) type of UGT1A1:&#xD;
&#xD;
      Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1,&#xD;
      follow by irinotecan (180 mg/m2 as a 120-min IV infusion), LV (400 mg/m2 IV infusion over 2&#xD;
      hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
&#xD;
      After 2 cycles of each different dose of irinotecan, we will observe the adverse effects&#xD;
      (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will&#xD;
      escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240&#xD;
      mg/m2.&#xD;
&#xD;
      The (7,7) type of UGT1A1:&#xD;
&#xD;
      Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1,&#xD;
      follow by irinotecan (120 mg/m2 as a 120-min IV infusion), LV (400 mg/m2 IV infusion over 2&#xD;
      hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
&#xD;
      After 2 cycles of each different dose of irinotecan, we will observe the adverse effects&#xD;
      (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will&#xD;
      escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180&#xD;
      mg/m2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2014</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>three to six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rates</measure>
    <time_frame>three to six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>three to six months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>UGT1A1 genotyping (6,6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UGTA1T1 genotyping (6,7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UGTA1T1 genotyping (7,7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UGT1A1 non-genotyping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will maintain the dosage of irinotecan by 180mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UGT1A1 genotyping (6,6)</intervention_name>
    <description>The investigators will use the regimen as following:&#xD;
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2.</description>
    <arm_group_label>UGT1A1 genotyping (6,6)</arm_group_label>
    <other_name>UGT1A1*1*1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UGTIA1 genotyping (6,7)</intervention_name>
    <description>The investigators will use the regimen as following:&#xD;
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2.</description>
    <arm_group_label>UGTA1T1 genotyping (6,7)</arm_group_label>
    <other_name>UGT1A1*1*28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UGTIA1 genotyping (7,7)</intervention_name>
    <description>The investigators will use the regimen as following:&#xD;
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.&#xD;
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2.</description>
    <arm_group_label>UGTA1T1 genotyping (7,7)</arm_group_label>
    <other_name>UGT1A1*28*28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UGT1A1 non-genotyping</intervention_name>
    <description>The investigators will use the regimen as following:&#xD;
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.</description>
    <arm_group_label>UGT1A1 non-genotyping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab (Avastin)</intervention_name>
    <description>bevacizumab as target therapy</description>
    <arm_group_label>UGT1A1 genotyping (6,6)</arm_group_label>
    <arm_group_label>UGT1A1 non-genotyping</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (6,7)</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (7,7)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>irinotecan as escalating dose according to UGT1A1 genotyping</description>
    <arm_group_label>UGT1A1 genotyping (6,6)</arm_group_label>
    <arm_group_label>UGT1A1 non-genotyping</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (6,7)</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (7,7)</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>combined with 5-FU</description>
    <arm_group_label>UGT1A1 genotyping (6,6)</arm_group_label>
    <arm_group_label>UGT1A1 non-genotyping</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (6,7)</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (7,7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>combined with irinotecan</description>
    <arm_group_label>UGT1A1 genotyping (6,6)</arm_group_label>
    <arm_group_label>UGT1A1 non-genotyping</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (6,7)</arm_group_label>
    <arm_group_label>UGTA1T1 genotyping (7,7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 y/o ≦ Age ≦ 80y/o&#xD;
&#xD;
          2. Either metachronous or synchronous mCRC can be enrolled&#xD;
&#xD;
          3. Female patients need not ready to be pregnant or breastfeeding&#xD;
&#xD;
          4. No major underlying diseases (such as cardiovascular, cerebrovascular, malignant&#xD;
             hypertension, kidney, liver and other major diseases)&#xD;
&#xD;
          5. mCRC be proven by pathologists or radiologists&#xD;
&#xD;
          6. Subjects are willing to sign an inform consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not meet the including criteria or unwilling to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ho Memorial Hospital, Kaohsiung Medical University:</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>October 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Jaw-Yuan Wang, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

